Ibrance (palbociclib) - Pfizer
Ibrance: Data from P3 PALLAS trial (NCT02513394) for HR+/HER2- breast cancer in early 2021 (Pfizer) - Jan 28, 2020 - Q4 2019 Results 
P3 data
https://s21.q4cdn.com/317678438/files/doc_financials/2019/q4/Q4-2019-Earnings-Charts-FINAL.pdf
 
Jan 28, 2020
 
 
781042a7-a836-47c4-8516-1db09485c313.png